{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:05:47Z","timestamp":1792044347380,"version":"4.4.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.beem.2026.102100","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:56:43Z","timestamp":1774339003000},"page":"102100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Resistant prolactinomas"],"prefix":"10.1016","volume":"40","author":[{"given":"Susan L.","family":"Samson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.beem.2026.102100_bib1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib2","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1530\/eje.1.02107","article-title":"Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data","volume":"154","author":"Buurman","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2026.102100_bib4","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2026.102100_bib5","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2026.102100_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beem.2026.102100_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.acvd.2012.06.007","article-title":"Multiple valvular regurgitation associated with bromocriptine therapy","volume":"107","author":"Cautres","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib10","first-page":"411","article-title":"Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l\u2032Hypophyse","volume":"61","author":"Rohmer","year":"2000","journal-title":"Ann Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib11","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1210\/clinem\/dgad545","article-title":"Ropinirole for the treatment of hyperprolactinemia: a dose-escalation study of efficacy and tolerability","volume":"109","author":"Heneghan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bcp.13802","article-title":"Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas","volume":"85","author":"Liu","year":"2019","journal-title":"Br J Clin Pharm"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1210\/clinem\/dgaf624","article-title":"Approach to the patient with dopamine-resistant microprolactinoma","volume":"111","author":"Glezer","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11102-023-01305-8","article-title":"Refractory lactotroph adenomas","volume":"26","author":"Urwyler","year":"2023","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.beem.2026.102100_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102883","article-title":"Prolactinomas resistant to dopamine agonists: pathophysiology and treatment","volume":"54","author":"Shimon","year":"2023","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib19","first-page":"31","article-title":"Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man","volume":"108","author":"Laboy-Ortiz","year":"2016","journal-title":"Bol Asoc Med P R"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11102-009-0168-0","article-title":"Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review","volume":"14","author":"Behan","year":"2011","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.beem.2026.102100_bib21","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/ejendo\/lvaf100","article-title":"Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas","volume":"192","author":"Raverot","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","article-title":"Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours","volume":"189","author":"Simon","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12020-021-02744-8","article-title":"Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas","volume":"74","author":"Wright","year":"2021","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s42000-019-00154-0","article-title":"Acidophil stem cell pituitary adenoma: a case report and literature review","volume":"18","author":"Annapurni","year":"2019","journal-title":"Horm (Athens)"},{"key":"10.1016\/j.beem.2026.102100_bib25","first-page":"116","article-title":"Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma","volume":"2","author":"Dessimoz","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.beem.2026.102100_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24129920","article-title":"Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas","volume":"24","author":"Voltan","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.beem.2026.102100_bib27","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4158\/EP15938.DSC","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology Disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia","volume":"21","author":"Samson","year":"2015","journal-title":"Endocr Pr"},{"key":"10.1016\/j.beem.2026.102100_bib28","article-title":"Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview","volume":"2013","author":"Elenkova","year":"2013","journal-title":"Case Rep Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0032-1333232","article-title":"Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance","volume":"121","author":"Elenkova","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib30","first-page":"2010","article-title":"Role of prolactin\/adenoma maximum diameter and prolactin\/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.beem.2026.102100_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.901385","article-title":"Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else","volume":"13","author":"Cho","year":"2022","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","article-title":"Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy","volume":"64","author":"Delgrange","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2026.102100_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1242588","article-title":"The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene","volume":"14","author":"Vroonen","year":"2023","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12020-022-03080-1","article-title":"Resistant prolactinomas: a case series of 26 patients","volume":"77","author":"Eshkoli","year":"2022","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.beem.2026.102100_bib35","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2026.102100_bib36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00701-005-0498-2","article-title":"Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance","volume":"147","author":"Delgrange","year":"2005","journal-title":"Acta Neurochir"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12020-018-1765-3","article-title":"T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists","volume":"63","author":"Burlacu","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.beem.2026.102100_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","article-title":"Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference","volume":"57","author":"Kreutz","year":"2015","journal-title":"Neuroradiology"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verges","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/EJE-07-0348","article-title":"The clinical, pathological, and genetic features of familial isolated pituitary adenomas","volume":"157","author":"Beckers","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2026.102100_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2213-8587(25)00118-4","article-title":"Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis","volume":"13","author":"English","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2026.102100_bib43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-8587(25)00119-6","article-title":"Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice","volume":"13","author":"Brandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib44","article-title":"Association of primary hyperparathyroidism with pituitary adenoma and management issues","volume":"39","author":"Das","year":"2025","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2026.102100_bib45","doi-asserted-by":"crossref","first-page":"e1482","DOI":"10.1210\/clinem\/dgae055","article-title":"Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review","volume":"109","author":"Chevalier","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-21-0075","article-title":"Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas","volume":"185","author":"Martinez de LaPiscina","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/EJE-11-0304","article-title":"High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas","volume":"165","author":"Tichomirowa","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-07-0806","article-title":"Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas","volume":"158","author":"Fusco","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib49","first-page":"314","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","author":"Shimazu","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2026.102100_bib51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2826.1996.04902.x","article-title":"Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas","volume":"8","author":"Caccavelli","year":"1996","journal-title":"J Neuroendocr"},{"issue":"6","key":"10.1016\/j.beem.2026.102100_bib52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11102-012-0436-2","article-title":"Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior","volume":"16","author":"Akinci","year":"2013","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11102-023-01301-y","article-title":"Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis","volume":"26","author":"Ben-Shlomo","year":"2023","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.beem.2026.102100_bib55","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma","volume":"87","author":"Gillam","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2026.102100_bib56","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib57","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology","volume":"90","author":"Steeds","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.beem.2026.102100_bib58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1755-5922.2010.00169.x","article-title":"Regression of cardiac valvulopathy related to ergot-derived dopamine agonists","volume":"29","author":"Zanettini","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.beem.2026.102100_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpsychires.2026.01.041","article-title":"Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic","volume":"195","author":"Lydiatt","year":"2026","journal-title":"J Psychiatr Res"},{"issue":"8","key":"10.1016\/j.beem.2026.102100_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11102-022-01221-3","article-title":"The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus","volume":"25","author":"Abou-Al-Shaar","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.beem.2026.102100_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-025-01580-7","article-title":"Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?","volume":"28","author":"Agrawal","year":"2025","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1227\/01.NEU.0000223445.22938.BD","article-title":"Gamma knife radiosurgery for medically and surgically refractory prolactinomas","volume":"59","author":"Pouratian","year":"2006","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib65","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3171\/2021.2.JNS204440","article-title":"Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations","volume":"136","author":"Mathieu","year":"2022","journal-title":"J Neurosurg"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib66","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3171\/2019.4.JNS183443","article-title":"The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study","volume":"133","author":"Hung","year":"2020","journal-title":"J Neurosurg"},{"issue":"3S","key":"10.1016\/j.beem.2026.102100_bib67","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1227\/neu.0000000000003582","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines for the role of radiosurgery for patients with functioning pituitary adenomas","volume":"97","author":"Green","year":"2025","journal-title":"Neurosurgery"},{"issue":"9","key":"10.1016\/j.beem.2026.102100_bib68","first-page":"3268","article-title":"Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas","volume":"84","author":"Jaquet","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","article-title":"Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma","volume":"14","author":"Fusco","year":"2011","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102100_bib71","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib72","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2026.102100_bib73","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors","volume":"100","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","article-title":"Pasireotide: a potential therapeutic alternative for resistant prolactinoma","volume":"80","author":"Lasolle","year":"2019","journal-title":"Ann Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib75","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-19-0359","article-title":"Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors","volume":"181","author":"Raverot","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib76","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2026.102100_bib77","doi-asserted-by":"crossref","first-page":"697","DOI":"10.5603\/ep.101797","article-title":"Pasireotide treatment in giant prolactinoma resistant to dopamine agonists","volume":"75","author":"Komisarz-Calik","year":"2024","journal-title":"Endokrynol Pol"},{"issue":"13","key":"10.1016\/j.beem.2026.102100_bib78","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-016-0615-y","article-title":"Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"76","author":"Samson","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1677\/joe.0.1510175","article-title":"Cellular receptors for sex steroids in human pituitary adenomas","volume":"151","author":"Jaffrain-Rea","year":"1996","journal-title":"J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1009903603495","article-title":"Estrogen receptors in prolactinomas: a clinico-pathological study","volume":"1","author":"Kaptain","year":"1999","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.beem.2026.102100_bib81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/15275","article-title":"Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis","volume":"5","author":"Heaney","year":"1999","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib82","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI0214264","article-title":"Functional role of estrogen in pituitary tumor pathogenesis","volume":"109","author":"Heaney","year":"2002","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.beem.2026.102100_bib83","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4158\/EP-2018-0321","article-title":"The effect of raloxifene on serum prolactin level in patients with prolactinoma","volume":"25","author":"Choudhary","year":"2019","journal-title":"Endocr Pr"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib84","first-page":"491","article-title":"Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen","volume":"101","author":"Volker","year":"1982","journal-title":"Acta Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib85","first-page":"65","article-title":"Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine","volume":"15","author":"Yamashita","year":"1987","journal-title":"No Shinkei Geka"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib86","first-page":"339","article-title":"Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas","volume":"34","author":"Lamberts","year":"1982","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib87","article-title":"Effect of tamoxifen on the management of dopamine agonist-resistant prolactinomas: a systematic review","volume":"15","author":"Bazuhair","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.beem.2026.102100_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.inat.2020.100777","article-title":"Dopamine agonist and tamoxifen combination therapy for a prolactinsecreting pituitary tumor resistant to dopamine agonist monotherapy: case report and review","volume":"21","author":"Christian","year":"2020","journal-title":"Interdiscip Neurosurg"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib89","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","article-title":"Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists","volume":"27","author":"Constantinescu","year":"2024","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2026.102100_bib90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1210\/jcem-64-2-391","article-title":"Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen","volume":"64","author":"Prior","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2026.102100_bib91","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40618-023-02231-z","article-title":"Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review","volume":"47","author":"Zuniga","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-007-0065-3","article-title":"Aromatase cytochrome P450 enzyme expression in human pituitary","volume":"11","author":"Kadioglu","year":"2008","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2026.102100_bib93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12020-015-0537-6","article-title":"Localization of the aromatase enzyme expression in the human pituitary gland and its effect on growth hormone, prolactin, and thyroid stimulating hormone axis","volume":"49","author":"Caglar","year":"2015","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.beem.2026.102100_bib94","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11102-021-01165-0","article-title":"Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients","volume":"24","author":"Ceccato","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2026.102100_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041437","article-title":"The role of aromatase inhibitors in male prolactinoma","volume":"12","author":"Akirov","year":"2023","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.beem.2026.102100_bib96","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/jc.2009-0739","article-title":"Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels","volume":"94","author":"Burnett-Bowie","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib97","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2265.2008.03327.x","article-title":"Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Burnett-Bowie","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2026.102100_bib98","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1111\/jcmm.13963","article-title":"Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts","volume":"22","author":"Gao","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.beem.2026.102100_bib99","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12020-014-0428-2","article-title":"The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study","volume":"49","author":"Krysiak","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2026.102100_bib100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.wneu.2018.02.188","article-title":"Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant prolactinomas: pilot study","volume":"115","author":"Liu","year":"2018","journal-title":"World Neurosurg"},{"issue":"10","key":"10.1016\/j.beem.2026.102100_bib101","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1210\/jc.2017-00627","article-title":"Pituitary tumor suppression by combination of cabergoline and chloroquine","volume":"102","author":"Lin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102100_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.955100","article-title":"Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report","volume":"13","author":"Lin","year":"2022","journal-title":"Front Endocrinol"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:20:35Z","timestamp":1788866435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X26000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521690X26000217"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102100","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant prolactinomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102100"}}